nach oben

Heart Failure Reviews

Erschienen in:

10.05.2018

Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review

verfasst von: Abdosaleh Jafari, Aziz Rezapour, Marjan Hajahmadi

Erschienen in: Heart Failure Reviews | Ausgabe 5/2018

Einloggen, um Zugang zu erhalten

Abstract

Measuring the level of B-type natriuretic peptide (BNP), as a guide to pharmacotherapy, can increase the survival of patients with heart failure. This study is aimed at systematically reviewing the studies conducted on the cost-effectiveness of BNP-guided care in patients with heart failure. Using the systematic review method, we reviewed the published studies on the cost-effectiveness of BNP-guided care in patients with heart failure during the years 2004 to 2017. The results showed that all studies clearly stated the time horizon of the study and included direct medical costs in their analysis. In addition, most of the studies used the Markov model. The quality-adjusted life years (QALYs) were the main outcome used for measuring the effectiveness. The studies reported various ranges of the incremental cost-effectiveness ratio (ICER); accordingly, the highest ratio was observed in the USA ($32,748) and the lowest ratio was observed in Canada ($6251). Although the results of the studies were different in terms of a number of aspects, such as the viewpoint of the study, the study horizons, and the costs of expenditure items, they reached similar results. Based on the results of the present study, it seems that the use of BNP or N-terminal pro-BNP (NT-pro-BNP) in patients with heart failure may reduce cost compared to the symptom-based clinical care and increase QALY. In this regard, these studies were designed and conducted in high-income countries; thus, the application of these results in low- and middle-income countries will be limited.

Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A (2011) Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation 123(8):933–944. https://doi.org/10.1161/CIR.0b013e31820a55f5 PubMedCrossRef

Rathi S, Deedwania PC (2012) The epidemiology and pathophysiology of heart failure. Medical Clinics 96(5):881–890. https://doi.org/10.1016/j.mcna.2012.07.011 PubMedCrossRef

Stewart S, MacIntyre K, Capewell S, McMurray J (2003) Heart failure and the aging population: an increasing burden in the 21st century? Heart 89(1):49–53PubMedPubMedCentralCrossRef

Chung M, Asher R, Yamada D, Eagle K, Podrid P, Kowey P (2001) Arrhythmias after cardiac and non-cardiac surgery. Podrid P, Kowey P Cardiac arrhythmia. 2nd ed Philadelphia: Lippincott Williams Wilkins:631–638

Cook C, Cole G, Asaria P, Jabbour R, Francis DP (2014) The annual global economic burden of heart failure. Int J Cardiol 171(3):368–376. https://doi.org/10.1016/j.ijcard.2013.12.028 PubMedCrossRef

Kelly BB, Fuster V (2010) Promoting cardiovascular health in the developing world: a critical challenge to achieve global health. National Academies Press,

Heidenreich PA, Albert NM, Allen LA, Bluemke DA, Butler J, Fonarow GC, Ikonomidis JS, Khavjou O, Konstam MA, Maddox TM (2013) Forecasting the impact of heart failure in the United States: a policy statement from the American Heart Association. Circulation: Heart Failure 6(3):606–619. https://doi.org/10.1161/HHF.0b013e318291329a CrossRef

Friedewald VE, Kornman KS, Beck JD, Genco R, Goldfine A, Libby P, Offenbacher S, Ridker PM, Van Dyke TE, Roberts WC (2009) The American Journal of Cardiology and Journal of Periodontology editors’ consensus: periodontitis and atherosclerotic cardiovascular disease. Am J Cardiol 104:59–68. https://doi.org/10.1016/j.amjcard.2009.05.002 PubMedCrossRef

Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL (2003) Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 107(3):499–511PubMedCrossRef

10.

Erbel R, Schweizer P, Krebs W, Meyer J, Effert S (1984) Sensitivity and specificity of two dimensional echocardiography in detection of impaired left ventricular function. Eur Heart J 5(6):477–489PubMedCrossRef

11.

Sabatasso S, Vaucher P, Augsburger M, Donzé N, Mangin P, Michaud K (2011) Sensitivity and specificity of NT-proBNP to detect heart failure at post mortem examination. Int J Legal Med 125(6):849–856. https://doi.org/10.1007/s00414-011-0581-6 PubMedPubMedCentralCrossRef

12.

Dieplinger B, Gegenhuber A, Haltmayer M, Mueller T (2009) Evaluation of novel biomarkers for the diagnosis of acute destabilised heart failure in patients with shortness of breath. Heart 95(18):1508–1513. https://doi.org/10.1136/hrt.2009.170696 PubMedCrossRef

13.

Felker GM, Hasselblad V, Hernandez AF, O'connor CM (2009) Biomarker-guided therapy in chronic heart failure: a meta-analysis of randomized controlled trials. Am Heart J 158(3):422–430. https://doi.org/10.1016/j.ahj.2009.06.018 PubMedCrossRef

14.

Lainchbury JG, Troughton RW, Strangman KM, Frampton CM, Pilbrow A, Yandle TG, Hamid AK, Nicholls MG, Richards AM (2009) N-terminal pro–B-type natriuretic peptide-guided treatment for chronic heart failure: results from the BATTLESCARRED (NT-proBNP–assisted treatment to lessen serial cardiac readmissions and death) trial. J Am Coll Cardiol 55(1):53–60. https://doi.org/10.1016/j.jacc.2009.02.095 PubMedCrossRef

15.

Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, Vuillomenet A, Jeker U, Dubach P, Beer H (2009) BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 301(4):383–392. https://doi.org/10.1001/jama.2009.2 PubMedCrossRef

16.

Porapakkham P, Porapakkham P, Zimmet H, Billah B, Krum H (2010) B-type natriuretic peptide-guided heart failure therapy: a meta-analysis. Arch Intern Med 170(6):507–514. https://doi.org/10.1001/archinternmed.2010.35 PubMedCrossRef

17.

Cameli M, Lisi M, Mondillo S, Padeletti M, Ballo P, Tsioulpas C, Bernazzali S, Maccherini M (2010) Left atrial longitudinal strain by speckle tracking echocardiography correlates well with left ventricular filling pressures in patients with heart failure. Cardiovascular Ultrasound 8(1):14. https://doi.org/10.1186/1476-7120-8-14 PubMedPubMedCentralCrossRef

18.

Dokainish H, Zoghbi WA, Ambriz E, Lakkis NM, Quinones MA, Nagueh SF (2006) Comparative cost-effectiveness of B-type natriuretic peptide and echocardiography for predicting outcome in patients with congestive heart failure. Am J Cardiol 97(3):400–403. https://doi.org/10.1016/j.amjcard.2005.08.060 PubMedCrossRef

19.

Almahmoud MF, O'Neal WT, Qureshi W, Soliman EZ (2015) Electrocardiographic versus echocardiographic left ventricular hypertrophy in prediction of congestive heart failure in the elderly. Clin Cardiol 38(6):365–370. https://doi.org/10.1002/clc.22402 PubMedCrossRef

20.

Munyandu N (2015) An echocardiography audit to determine and characterise rheumatic heart disease lesions seen in 2012.

21.

Yang H, Marwick TH, Wang Y, Nolan M, Negishi K, Khan F, Okin PM (2017) Association between electrocardiographic and echocardiographic markers of stage B heart failure and cardiovascular outcome. ESC Heart Failure 4:417–431. https://doi.org/10.1002/ehf2.12151 PubMedPubMedCentralCrossRef

22.

Tanaray B, Eslami M, Salehi M, Jahanzad I, Emami M (2010) Relationship of plasma level of NT-ProBNP with development of AF in CABG patients. Tehran University Medical Sci 68(7):384–390

23.

Alimohamadian MRM (2013) NT probnp the newest biomarker in heart failure. journal of laboratory tests 97(1):1–5

24.

Doust J, Lehman R, Glasziou P (2006) The role of BNP testing in heart failure. Am Fam Physician 74(11):1893–1898PubMed

25.

kbR MM, sadat H, Namazi M, Safi M, Vakili H (2009) The study of diagnostic value of NT-proBNP in diagnosis of heart failure in patients with the main complaint of dyspnea in Modarres hospital in 2007–2008. J Shahid Behshti University Medical Sci 5(71):241–245

26.

Adlbrecht C, Huelsmann M, Berger R, Moertl D, Strunk G, Oesterle A, Ahmadi R, Szucs T, Pacher R (2011) Cost analysis and cost-effectiveness of NT-proBNP-guided heart failure specialist care in addition to home-based nurse care. Eur J Clin Investig 41(3):315–322. https://doi.org/10.1111/j.1365-2362.2010.02412.x CrossRef

27.

Lim TK, Dwivedi G, Hayat S, Collinson PO, Senior R (2007) Cost effectiveness of the B type natriuretic peptide, electrocardiography, and portable echocardiography for the assessment of patients from the community with suspected heart failure. Echocardiography 24(3):228–236. https://doi.org/10.1111/j.1540-8175.2007.00398.x PubMedCrossRef

28.

Sim V, Hampton D, Phillips C, Lo S-N, Vasishta S, Davies J, Penney M (2003) The use of brain natriuretic peptide as a screening test for left ventricular systolic dysfunction—cost-effectiveness in relation to open access echocardiography. Fam Pract 20(5):570–574PubMedCrossRef

29.

Gray AM, Clarke PM, Wolstenholme JL, Wordsworth S (2010) Applied methods of cost-effectiveness analysis in healthcare, vol 3. OUP Oxford,

30.

Callahan KP, Bridges JF (2012) Using comparative effectiveness research to inform decision-making: is there a role of economic evaluation? J Comparative Effectiveness Res 1(4):299–301. https://doi.org/10.2217/cer.12.33 CrossRef

31.

Eddama O, Coast J (2009) Use of economic evaluation in local health care decision-making in England: a qualitative investigation. Health Policy 89(3):261–270. https://doi.org/10.1016/j.healthpol.2008.06.004 PubMedCrossRef

32.

Goeree R, Diaby V (2013) Introduction to health economics and decision-making: is economics relevant for the frontline clinician? Best Pract Res Clin Gastroenterol 27(6):831–844. https://doi.org/10.1016/j.bpg.2013.08.016 PubMedCrossRef

33.

Hutton J (2012) ‘Health economics’ and the evolution of economic evaluation of health technologies. Health Econ 21(1):13–18. https://doi.org/10.1002/hec.1818 PubMedCrossRef

34.

Lessard C, Contandriopoulos A-P, Beaulieu M-D (2010) The role (or not) of economic evaluation at the micro level: can Bourdieu’s theory provide a way forward for clinical decision-making? Soc Sci Med 70(12):1948–1956. https://doi.org/10.1016/j.socscimed.2010.03.013 PubMedCrossRef

35.

Almasiankia A, Kavosi Z, Keshtkaran A, Jafari A, Goodarzi S (2015) Equity in health care financing among Iranian households. Shiraz E-Medical Journal 16 (11, 12)

36.

Jahromi NN, Jafari A, Kavosi Z, Shokrpour N, Sajjadnia Z, Ravangard R (2016) Demand for dental services in Shiraz, Iran, 2013. Health Care Manager 35(4):340–349. https://doi.org/10.1097/HCM.0000000000000136 PubMedCrossRef

37.

Kavosi Z, Mohammadbeigi A, Ramezani-Doroh V, Hatam N, Jafari A, Firoozjahantighi A (2015) Horizontal inequity in access to outpatient services among Shiraz City residents, Iran. J Res Health Sci 15(1):37–41PubMed

38.

Ravangard R, Hatam N, Teimourizad A, Jafari A (2014) Factors affecting the technical efficiency of health systems: a case study of Economic Cooperation Organization (ECO) countries (2004–10). Int J health Policy Management 3(2):63–69. https://doi.org/10.15171/ijhpm.2014.60 CrossRef

39.

Drummond MF, Sculpher MJ, Claxton K, Stoddart GL, Torrance GW (2015) Methods for the economic evaluation of health care programmes. Oxford university press,

40.

Rezapour A, Jafari A, Mirmasoudi K, Talebianpour H (2017) Quality assessment of published studies in Iranian journals related to economic evaluation in health care programs based on Drummond’s checklist: a narrative review. Iranian J Medical Sci 41(2):427–436

41.

Heidenreich PA, Gubens MA, Fonarow GC, Konstam MA, Stevenson LW, Shekelle PG (2004) Cost-effectiveness of screening with B-type natriuretic peptide to identify patients with reduced left ventricular ejection fraction. J Am Coll Cardiol 43(6):1019–1026. https://doi.org/10.1016/j.jacc.2003.10.043 PubMedCrossRef

42.

Laramée P, Wonderling D, Swain S, Al-Mohammad A, Mant J (2013) Cost-effectiveness analysis of serial measurement of circulating natriuretic peptide concentration in chronic heart failure. Heart 99(4):267–271. https://doi.org/10.1136/heartjnl-2012-302692 PubMedCrossRef

43.

Moertl D, Steiner S, Coyle D, Berger R (2013) Cost-utility analysis of NT-proBNP-guided multidisciplinary care in chronic heart failure. Int J Technol Assess Health Care 29(1):3–11. https://doi.org/10.1017/S0266462312000712 PubMedCrossRef

44.

Mohiuddin S, Reeves B, Pufulete M, Maishman R, Dayer M, Macleod J, McDonagh T, Purdy S, Rogers C, Hollingworth W (2016) Model-based cost-effectiveness analysis of B-type natriuretic peptide-guided care in patients with heart failure. BMJ Open 6(12):1–10. https://doi.org/10.1136/bmjopen-2016-014010 CrossRef

45.

Morimoto T, Hayashino Y, Shimbo T, Izumi T, Fukui T (2004) Is B-type natriuretic peptide-guided heart failure management cost-effective? Int J Cardiol 96(2):177–181. https://doi.org/10.1016/j.ijcard.2003.05.036 PubMedCrossRef

46.

Sanders-van Wijk S, van Asselt AD, Rickli H, Estlinbaum W, Erne P, Rickenbacher P, Vuillomenet A, Peter M, Pfisterer ME, Brunner-La Rocca H-P (2013) Cost-effectiveness of N-terminal pro-B-type natriuretic-guided therapy in elderly heart failure patients: results from TIME-CHF (Trial of Intensified versus Standard Medical Therapy in Elderly Patients with Congestive Heart Failure). JACC: Heart Failure 1(1):64–71. https://doi.org/10.1016/j.jchf.2012.08.002 PubMedCrossRef

47.

Siebert U, Januzzi JL, Beinfeld MT, Cameron R, Gazelle GS (2006) Cost-effectiveness of using N-terminal pro-brain natriuretic peptide to guide the diagnostic assessment and management of dyspneic patients in the emergency department. Am J Cardiol 98(6):800–805. https://doi.org/10.1016/j.amjcard.2006.06.005 PubMedCrossRef

48.

Augustovski F, Iglesias C, Manca A, Drummond M, Rubinstein A, Martií SG (2009) Barriers to generalizability of health economic evaluations in Latin America and the Caribbean region. PharmacoEconomics 27(11):919–929. https://doi.org/10.2165/11313670-000000000-00000 PubMedCrossRef

49.

Baltussen RM, Hutubessy RC, Evans DB, Murray CJ (2002) Uncertainty in cost-effectiveness analysis: probabilistic uncertainty analysis and stochastic league tables. Int J Technol Assess Health Care 18(1):112–119PubMed

50.

Drummond M, Manca A, Sculpher M (2005) Increasing the generalizability of economic evaluations: recommendations for the design, analysis, and reporting of studies. Int J Technol Assess Health Care 21(2):165–171PubMed

51.

Ghabri S, Hamers FF, Josselin J-M, Harousseau J-L (2014) Exploring uncertainty in economic evaluation of medicines: a review of the first manufacturers’ submissions to the French National Authority for Health (Has). Value Health 17(7):A441–A442. https://doi.org/10.1016/j.jval.2014.08.1160 PubMedCrossRef

52.

Limwattananon S (2011) Handling uncertainty of the economic evaluation result: sensitivity analysis. J Med Assoc Thail 91(6):59

53.

Limwattananon S (2014) Sensitivity analysis for handling uncertainty in an economic evaluation. J Medical Assoc Thailand Chotmaihet Thangphaet 97:S59–S64

54.

Ruggeri M, Manca A, Coretti S, Codella P, Iacopino V, Romano F, Mascia D, Orlando V, Cicchetti A (2015) Investigating the generalizability of economic evaluations conducted in Italy: a critical review. Value Health 18(5):709–720. https://doi.org/10.1016/j.jval.2015.03.1795 PubMedCrossRef

55.

ENd S, Silva MT, Pereira MG (2017) Uncertainty in economic evaluation studies. Epidemiologia e Serviços de Saúde 26(1):211–213. https://doi.org/10.5123/S1679-49742017000100022 CrossRef

56.

Scalone L, Cortesi PA (2016) About the reliability of the critical review to investigate the generalizability of economic evaluations conducted in Italy. Value Health 19(5):697. https://doi.org/10.1016/j.jval.2016.03.1833 PubMedCrossRef

57.

Hatam N, Dehghani M, Habibian M, Jafari A (2015) Cost-utility analysis of IEV drug regimen versus ESHAP drug regimen for the patients with relapsed and refractory Hodgkin and non-Hodgkin’s lymphoma in Iran. Iranian J Cancer Prevention 8(5):1–8. https://doi.org/10.17795/ijcp-4061 CrossRef

58.

Gaziano TA, Bitton A, Anand S, Abrahams-Gessel S, Murphy A (2010) Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol 35(2):72–115. https://doi.org/10.1016/j.cpcardiol.2009.10.002 PubMedPubMedCentralCrossRef

Titel: Cost-effectiveness of B-type natriuretic peptide-guided care in patients with heart failure: a systematic review
verfasst von: Abdosaleh Jafari
Aziz Rezapour
Marjan Hajahmadi
Publikationsdatum: 10.05.2018
Verlag: Springer US
Erschienen in: Heart Failure Reviews / Ausgabe 5/2018
Print ISSN: 1382-4147
Elektronische ISSN: 1573-7322
DOI: https://doi.org/10.1007/s10741-018-9710-3

Neu im Fachgebiet Kardiologie

Screening-Mammografie offenbart erhöhtes Herz-Kreislauf-Risiko

26.04.2024 Mammografie Nachrichten

Routinemäßige Mammografien helfen, Brustkrebs frühzeitig zu erkennen. Anhand der Röntgenuntersuchung lassen sich aber auch kardiovaskuläre Risikopatientinnen identifizieren. Als zuverlässiger Anhaltspunkt gilt die Verkalkung der Brustarterien.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Adipositas-Medikament auch gegen Schlafapnoe wirksam

24.04.2024 Adipositas Nachrichten

Der als Antidiabetikum sowie zum Gewichtsmanagement zugelassene Wirkstoff Tirzepatid hat in Studien bei adipösen Patienten auch schlafbezogene Atmungsstörungen deutlich reduziert, informiert der Hersteller in einer Vorab-Meldung zum Studienausgang.

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 5/2018

Postmortem cardiac magnetic resonance in sudden cardiac death

Author’s response to: letter to the editor

The role of arterial hypertension in development heart failure with preserved ejection fraction: just a risk factor or something more?

Role of cytokines and inflammation in heart function during health and disease